Clinical Trial

A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017)

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to learn what happens to calderasib levels in a person's body over time. Researchers will measure what happens to calderasib levels in the body when it is given to participants with hepatic (liver) impairment and healthy participants. Researchers also want to learn about the safety of MK-1084 when it is given to people with hepatic impairment and if people with hepatic impairment can tolerate it.
Protocol Amendment History 3 changes
critical Trial completed 2026-08-05
notable Enrollment reduced: 58 -> 32 participants 2026-08-05
minor Completion moved earlier: 2026-08-14 -> 2026-07-15 2026-08-05
Trial Details
NCT Number NCT07219550
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Healthy, Hepatic Impairment
Enrollment 32 participants
Start Date 2025-11-05
Primary Completion 2026-07-15 (estimated)
Study Completion 2026-07-15 (estimated)
Updated on ClinicalTrials.gov 2026-08-04